Functional Pulmonary Capillary Surface Area in BPA for CTEPH
Recruiting now NCT05719415
Run by Jewish General Hospital · for 18 to 75 · All sexes
What this study is about
Chronic thromboembolic pulmonary hypertension \[CTEPH\] is caused by pulmonary emboli that have enlarged in pulmonary arteries and have become organized into the vessel wall. Many patients with CTEPH are treated with balloon pulmonary angioplasty \[BPA\] which mechanically opens the narrow pulmonary arteries. It is unclear how much downstream functional pulmonary capillary surface area \[FCSA\] is recovered during BPA. The investigators plan to measure FCSAIn CTEPH patients, before and after a session of BPA.
Who can join (things the study team will check)
✅ You may be able to join if…
- All patients eligible for balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension
🚫 You may not be able to join if…
- Treatment with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers,
- Presence of patent foramen ovale
Where this trial is running
- David Langleben, Montreal, Quebec, Canada
Who to contact
David Langleben, MD · 5143407531 · david.langleben@mcgill.ca
It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT05719415.
Verify everything on the official ClinicalTrials.gov record. Page updated July 2026.